REFERENCES
- Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway. Proc Natl Acad Sci U S A. 1999; 96: 4240–4245
- Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000; 100: 387–390
- McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul Proc. 2006; 46: 249–279
- White MK, McCubrey JA. Suppression of apoptosis: Role in cell growth and neoplasia. Leukemia. 2001; 15: 1011–1021
- Aggerholm A, Gronbaek K, Guldberg P, Hokland P. Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Euro J Haematol. 2000; 65: 109–113
- Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression end Akt activation. Clin Cancer Res. 2007; 13: 3860–3867
- Dahia PLM, Aguiar RCT, Alberta J, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet. 1999; 8: 185–193
- Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999; 155: 1253–1260
- Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 104: 2492–2498
- Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003; 63: 2881–2890
- Yang L, Kuang LG, Zheng HC, et al. PTEN encoding product: A marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol 2003; 9: 35–39
- Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: Diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007; 22: 1251–1267
- Roskoski R. Signaling by Kit protein-tyrosine kinase: The stem cell factor receptor. Biochem Biophys Res Commun. 2005; 337: 1–13
- Wu CY, Sun MZ, Liu LJ, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003; 306: 1–12
- Koyama M, Oka T, Ouchida M, et al. Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest. 2003; 83: 1849–1858
- Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002; 62: 6390–6394
- Reddy J, Shivapurkar N, Takahashi T, et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 2005; 24: 732–736
- Gustafsson G, Langmark F, Pihkala U, Heyman M, de Verdier B, Lilleaas I. Childhood Cancer in the Nordic Countries, , et al. Nordic Society of Pediatric Haematology and Oncology, GothenburgSweden 1999; 83–152
- Fridberg M, Servin A, Anagnostaki L, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma. 2007; 48: 2221–2232
- Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukemia-initiating cells. Nature 2006; 441: 475–482
- Avellino R, Romano S, Parasole R, et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400–1406
- Yang J, Liu J, Zheng J, et al. A reappraisal by quantitative flow cytometry analysis of PTEN expression in acute leukemia. Leukemia 2007; 21: 2072–2074
- Mena-Duran AV, Togo SH, Bazhenova L, et al. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: A new prognostic factor. Br J Haematol 2005; 129: 791–794
- Amin HM, Hoshino K, Yang H, Lin Q, La R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-I (ShpI) is associated with progression of chronic myeloid leukemia. J Pathol 2007; 212: 402–410